Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874580 | 0.93 | CA2 (0.64) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3871788 | 0.89 | CA2 (0.55) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3872471 | 0.89 | CA2 (0.61) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3865630 | 0.88 | CA2 (0.66) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3866385 | 0.87 | CA2 (0.53) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3872468 | 0.87 | CA2 (0.59) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3869672 | 0.87 | CA2 (0.55) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3872170 | 0.87 | CA2 (0.59) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3868625 | 0.82 | CA2 (0.66) | CA2CA9MEN1CYP3A4ALOX15 | |
| SCHEMBL3873054 | 0.81 | CA2 (0.65) | CA2CA9MEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534780-B2 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-19 | — | — | US | claimed |
| US-20050288267-A1 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | claimed |
| US-7534780-B2 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20050288267-A1 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288267-A1 | Estradiol prodrugs | CYP19A1, ESR1, HSD17B11 | CA2 2551/4885CA9 1880/4885MEN1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.